As of 2025-07-03, the Intrinsic Value of Biotage AB (BIOT.ST) is 83.58 SEK. This BIOT.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 143.00 SEK, the upside of Biotage AB is -41.60%.
The range of the Intrinsic Value is 54.34 - 212.98 SEK
Based on its market price of 143.00 SEK and our intrinsic valuation, Biotage AB (BIOT.ST) is overvalued by 41.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 54.34 - 212.98 | 83.58 | -41.6% |
| DCF (Growth 10y) | 68.49 - 260.62 | 104.15 | -27.2% |
| DCF (EBITDA 5y) | 56.36 - 98.84 | 76.87 | -46.2% |
| DCF (EBITDA 10y) | 66.75 - 119.51 | 90.82 | -36.5% |
| Fair Value | 31.05 - 31.05 | 31.05 | -78.28% |
| P/E | 69.60 - 123.92 | 91.76 | -35.8% |
| EV/EBITDA | 40.27 - 100.70 | 65.97 | -53.9% |
| EPV | 58.00 - 84.80 | 71.40 | -50.1% |
| DDM - Stable | 35.03 - 195.18 | 115.11 | -19.5% |
| DDM - Multi | 48.98 - 204.21 | 78.14 | -45.4% |
| Market Cap (mil) | 11,447.15 |
| Beta | 0.94 |
| Outstanding shares (mil) | 80.05 |
| Enterprise Value (mil) | 11,265.15 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.42% |
| Cost of Debt | 4.25% |
| WACC | 7.33% |